Proteon Therapeutics Inc (NASDAQ:PRTO) Receives Consensus Recommendation of “Hold” from Analysts

Proteon Therapeutics Inc (NASDAQ:PRTO) has been assigned a consensus rating of “Hold” from the six research firms that are currently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $2.50.

Several equities analysts have weighed in on the company. Zacks Investment Research downgraded Proteon Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Cowen reaffirmed a “hold” rating on shares of Proteon Therapeutics in a research report on Wednesday, May 8th.

NASDAQ PRTO traded down $0.01 during trading on Tuesday, hitting $0.30. The stock had a trading volume of 170,200 shares, compared to its average volume of 929,870. The company has a market capitalization of $6.02 million, a P/E ratio of -0.26 and a beta of 0.42. The business’s 50 day moving average is $0.39. Proteon Therapeutics has a twelve month low of $0.28 and a twelve month high of $3.94.

Proteon Therapeutics (NASDAQ:PRTO) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.21). On average, research analysts expect that Proteon Therapeutics will post -0.59 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Proteon Therapeutics stock. Wedbush Securities Inc. lifted its stake in Proteon Therapeutics Inc (NASDAQ:PRTO) by 76.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 104,000 shares of the biopharmaceutical company’s stock after purchasing an additional 45,000 shares during the quarter. Wedbush Securities Inc. owned about 0.53% of Proteon Therapeutics worth $43,000 as of its most recent SEC filing. 23.10% of the stock is owned by institutional investors.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes.

Featured Article: What is the Consumer Price Index (CPI)?

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with's FREE daily email newsletter.